Related Experiment Videos
[Bioavailability and its significance in pharmacotherapy]
Anna Wiela-Hojeńska1, Krystyna Orzechowska-Juzwenko
1Katedra i Zakład Farmakologii Klinicznej, Akademii Medycznej we Wrocławiu.
Summary
This study explains drug bioavailability, focusing on how liver disease impacts drug absorption and requires dose adjustments to prevent toxicity. Key metrics include Area Under the Curve (AUC), maximum concentration (Cmax), and time to maximum concentration (tmax).
Area of Science:
- Pharmacokinetics
- Drug Metabolism
- Drug Absorption
Context:
- Bioavailability is a critical parameter in pharmacokinetics, influencing drug efficacy and safety.
- Understanding factors affecting drug absorption is essential for effective therapeutic outcomes.
- First-pass metabolism significantly impacts the systemic bioavailability of orally administered drugs.
Purpose:
- To provide a comprehensive overview of drug bioavailability.
- To elucidate the fundamental concepts and influencing factors of bioavailability.
- To highlight the quantitative measures of systemic bioavailability: Area Under the Curve (AUC), Cmax, and tmax.
Summary:
- Systemic bioavailability is quantified by AUC, Cmax, and tmax, reflecting the amount and rate of drug reaching circulation.
- Liver diseases can dramatically increase oral bioavailability for drugs undergoing extensive first-pass metabolism.
- Examples include propranolol, lidocaine, metoprolol, and verapamil, whose oral bioavailability is elevated in liver disease.
Impact:
- Liver disease necessitates reduced oral doses of specific drugs to prevent potential toxicity.
- This information is crucial for clinicians managing patients with hepatic impairment.
- Optimizing drug dosage in liver disease improves patient safety and therapeutic effectiveness.